Neeraj Agarwal, MD, on Castration-Resistant Prostate Cancer: Results From the COSMIC-021 Study of Cabozantinib and Atezolizumab
2020 Genitourinary Cancers SymposiumNeeraj Agarwal, MD, of the University of Utah Huntsman Cancer Institute, discusses trial findings that showed the combination of cabozantinib and atezolizumab had a tolerable safety profile and showed activity in men with metastatic disease. Further evaluation of cabozantinib and atezolizumab is planned in a phase III trial (Abstract 82).
Related Videos
Maha Hussain, MD, on Next-Generation Sequencing of Prostate Tumor Tissue: Results From the PROfound Study
Maha Hussain, MD, of the Robert H. Lurie Comprehensive Cancer Center of Northwestern University, discusses the first phase III clinical trial to demonstrate the feasibility o...
Hannah L. Rush, MBChB, on Prostate Cancer: Comparing Quality of Life in Patients Receiving Docetaxel or Abiraterone
Hannah L. Rush, MBChB, of the Clinical Trials Unit at University College London, discusses an analysis of the STAMPEDE trial, which showed that patients treated with abirater...
Toni K. Choueiri, MD, on COSMIC-313: Cabozantinib in Combination With Nivolumab/Ipilimumab in RCC
Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, describes a currently recruiting phase III study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimu...
Karim Fizazi, MD, PhD, on Prostate Cancer: Pain and Quality of Life in Patients Receiving Cabazitaxel vs Abiraterone or Enzalutamide
Karim Fizazi, MD, PhD, of the Institut Gustave Roussy, discusses results from the CARD study, which showed that cabazitaxel improved pain, time to pain progression, and sympt...
Jonathan E. Rosenberg, MD, on Locally Advanced or Metastatic Urothelial Carcinoma: Enfortumab Vedotin Plus Pembrolizumab
Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center, discusses study results which showed that, in first-line cisplatin-ineligible patients with metastatic u...
